Borealis Biosciences, a Vancouver, Canada-based RNA medicines company, expanded its Series A funding to $30M.
The round was led by Westlake BioPartners, bringing the total amount to $180M. Borealis also added three new board directors, David Allison, Ph.D., Tom Frohlich and Catherine Thut, Ph.D.
The company intends to use the funds to expand operations and its development efforts.
Led by newly appointed CEO Christian Hordo, Borealis provides facilities that include wet labs for molecular and cellular biology, vivarium space, chemistry and analytical capabilities. The initial 25+ team is made up of drug hunters with expertise in kidney disease, translational systems biology and data sciences, translational biology, chemistry, DMPK and pharmacology.
In August, the company emerged from stealth with $150m in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research collaboration funding from the pharma.
FinSMEs
19/12/2024